Stock Track | CSL LIMITED Plummets 5.01% Intraday After Cutting Earnings Outlook and Warning of $5 Billion Impairment

Stock Track
May 12

CSL LIMITED's stock plummeted 5.01% during intraday trading on Tuesday, extending a significant decline for the Australian biotech firm.

The sharp drop follows the company's announcement that it cut its annual profit forecast and warned of a substantial $5 billion impairment charge. This news triggered immediate negative reactions from major financial institutions.

Citi downgraded CSL's rating from "Buy" to "Neutral" and drastically reduced its price target from A$200.00 to A$110.00. Meanwhile, Morningstar analysts slashed their revenue and underlying net profit after tax forecasts for CSL by an average of 3% and 9% respectively over the next decade, citing a lack of sales momentum and the urgent need for the company to hire a new CEO with a compelling turnaround vision.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10